Long-Term Safety and Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder | Zendy

Floyd R. Sallee | Zendy; A. G. Lyne | Zendy; Timothy Wigal | Zendy; James J. McGough | Zendy

Open Access

Long-Term Safety and Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Author(s) -

Floyd R. Sallee,

A. G. Lyne,

Timothy Wigal,

James J. McGough

Publication year - 2009

Publication title -

journal of child and adolescent psychopharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.935

H-Index - 84

eISSN - 1557-8992

pISSN - 1044-5463

DOI - 10.1089/cap.2008.0080

Subject(s) - guanfacine , attention deficit hyperactivity disorder , adverse effect , attention deficit , medicine , extended release , safety profile , pediatrics , psychiatry , pharmacology , anesthesia , clonidine

Short-term, controlled studies of extended-release guanfacine (GXR), a selective alpha(2A)-adrenoreceptor agonist, demonstrate efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms as monotherapy. This 2-year open-label study was conducted to further assess the long-term safety and efficacy of GXR.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research